The finding that iloprost, in addition to the well-known vasodilator effect, can counteract CXCL10 release by human endothelial cells and fibroblasts and also downmodulate CXCL4 in early SSc might open new scenarios for early treatments in SSc. Here, CXCL10 is linked to systemic sclerosis.